Antisoma Cancer Drug Shows Good Phase II Prostate Data.

BioWorld International Correspondent

LONDON - Antisoma plc reported further clinical progress with its first-in-class vascular disrupting agent ASA404, announcing two-year survival of 33 percent in hormone refractory prostate cancer patients receiving ASA404 plus docetaxel, vs. 23 percent in the control group, which received docetaxel alone.

The hazard ratio expressing the relative risk of death in the two arms of the trial favored ASA404 at 0.8 percent, while median survival of the two groups was similar at 17 and 17.2 months, respectively.

The data added to earlier findings from the Phase II study, which showed a 59 percent prostate-specific antigen …